JUN 15 2001
PATENT & TRADEMARK OFFICE

Docket No. P1729C1

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

Co-Administration of a Thrombolytic and an Anti-CD18 Antibody

the specification of which was included in application U.S. Serial No. 09/811,384 filed on December 20, 2000 and was amended in the Preliminary Amendment submitted therewith.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate have a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s):			Priority Claimed Yes	Priority Claimed No
Number	Country	Day/Month/Year Filed		

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional applications(s) listed below:

60/093,038	23 January 1996
Application Ser. No.	Filing Date

I hereby claim the benefit under Title 35, United States Code, §120 of any United States applications(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

09/251,652	17 February 1999	Pending
Application Ser. No.	Filing Date	Status: Patented, Pending, Abandoned
08/788,800	22 January 1997	Granted
Application Ser. No.	Filing Date	Status: Patented, Pending, Abandoned

POWER OF ATTORNEY: As a named inventor, I hereby appoint all Attorney(s) and/or Agent(s) associated with the following Patent Office Issued Customer Number to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.



09157

PATENT TRADEMARK OFFICE

OIPE JC100 JUN 15 2001 PATENT & TRADEMARK OFFICE

Send correspondence to Genentech, Inc.
Attn: Richard B. Love
Telephone: (650) 225-5530

I hereby declare that all statements made herein of my own knowledge and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of Title 18 of the United States Code and that willful false statements may jeopardize the validity of the application or any patent issued thereon.

The undersigned hereby authorizes the U.S. attorney or agent named herein to accept and follow instructions from his foreign patent agent as to any action to be taken in the Patent and Trademark Office regarding this application without direct communication between the U.S. attorney or agent and the undersigned. In the event of a change in the persons from whom instructions may be taken, the U.S. attorney or agent named herein will be so notified by the undersigned.

Full name of sole or first inventor

Martin M. Bednar

Inventor's signature Date

Residence
33 Bartlett Bay Road, South Burlington, VT 05403

Citizenship
United States

Post Office Address
1 DNA Way
South San Francisco, CA 94080

Full name of second joint inventor, if any

Cordell E. Gross

Inventor's signature Date

Residence
30 Ledgewood Drive, Williston, Vermont 05495

Citizenship
United States

Post Office Address
1 DNA Way
South San Francisco, CA 94080

Full name of third joint inventor, if any

G. Roger Thomas

Inventor's signature Date

Residence
812 Park Avenue, Burlingame, California 94010

Citizenship
United States

Post Office Address
1 DNA Way
South San Francisco, CA 94080

Docket No. P1729C1

ASSIGNMENT

WHEREAS, Martin M. Bednar a citizen of United States, residing at 33 Bartlett Bay Road South Burlington, Vermont 05431, and Cordell Gross, a citizen of United States, residing at 30 Ledgewood Drive, Williston, Vermont 05495, and G. Roger Thomas, a citizen of United States, residing at 812 Park Avenue, Burlingame, California 94010, (hereinafter "ASSIGNORS"), have invented a new and useful invention in

Co-Administration of a Thrombolytic and An Anti-CD18 Antibody

for which an application 09/811,384 (Docket No. P1729C1) for Letters Patent has been filed by them on 20 December 2000; and

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, is desirous of acquiring an interest in and to said invention, and in and to the Letters Patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

That for good and valuable consideration the receipt of which is hereby acknowledged, the said ASSIGNORS have and do hereby sell, assign, transfer and set over unto the said GENENTECH, INC., its successors and assigns, the full and exclusive right, title and interest including all rights under the Paris Convention for the Protection of Industrial Property, in and to said invention, and in and to any and all Letters Patents to be granted and issued therefor or any continuation, division, renewal, or substitute thereof, and as to Letters Patents any reissue or re-examination thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other countries; and it has been and is hereby authorized and requested that the appropriate government agencies issue said Letters Patents to said GENENTECH, INC., in accordance with this Assignment.

Said ASSIGNORS covenant and agree to cooperate with GENENTECH, INC., to enable said GENENTECH, INC. to enjoy to the fullest extent the right, title and interest herein conveyed in the United States and foreign countries. Such cooperation by said ASSIGNORS includes prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said GENENTECH, INC., (a) for perfecting the right, title and interest herein conveyed; (b) for prosecuting any of said applications; (c) for filing and prosecuting applications for reissuance of any of said patents; (d) for interference or other priority proceedings involving said invention; and (e) for legal proceedings involving said invention and any applications therefor and any patents granted thereon, including without limitation opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by said ASSIGNORS in providing such cooperation shall be paid for by said GENENTECH, INC.

The terms and covenants of this assignment shall inure to the benefit of said GENENTECH, INC., its successors, assigns and other legal representatives, and shall be binding upon said ASSIGNORS, their respective heirs, legal representatives and assigns.

Said ASSIGNORS hereby warrant and represent that they have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

IN WITNESS WHEREOF we undersign as follows;

Dated: _____ _____
Martin M. Bednar

Dated: _____ _____
Cordell E. Gross

Dated: _____ _____
G. Roger Thomas